Tourmaline Bio Statistics
Total Valuation
Tourmaline Bio has a market cap or net worth of $405.36 million. The enterprise value is $156.25 million.
Important Dates
The last earnings date was Friday, May 2, 2025, before market open.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Tourmaline Bio has 25.69 million shares outstanding. The number of shares has increased by 144.29% in one year.
| Current Share Class | 25.69M |
| Shares Outstanding | 25.69M |
| Shares Change (YoY) | +144.29% |
| Shares Change (QoQ) | -0.40% |
| Owned by Insiders (%) | 8.46% |
| Owned by Institutions (%) | 64.30% |
| Float | 15.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 33.87, with a Debt / Equity ratio of 0.00.
| Current Ratio | 33.87 |
| Quick Ratio | 32.71 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.14% and return on invested capital (ROIC) is -19.39%.
| Return on Equity (ROE) | -26.14% |
| Return on Assets (ROA) | -19.03% |
| Return on Invested Capital (ROIC) | -19.39% |
| Return on Capital Employed (ROCE) | -35.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.12M |
| Employee Count | 74 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.83% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +8.83% |
| 50-Day Moving Average | 15.48 |
| 200-Day Moving Average | 19.18 |
| Relative Strength Index (RSI) | 50.43 |
| Average Volume (20 Days) | 337,535 |
Short Selling Information
The latest short interest is 3.19 million, so 12.42% of the outstanding shares have been sold short.
| Short Interest | 3.19M |
| Short Previous Month | 3.06M |
| Short % of Shares Out | 12.42% |
| Short % of Float | 20.49% |
| Short Ratio (days to cover) | 8.77 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -98.45M |
| Pretax Income | -35.69M |
| Net Income | -82.87M |
| EBITDA | -98.41M |
| EBIT | -98.45M |
| Earnings Per Share (EPS) | -$3.22 |
Full Income StatementBalance Sheet
The company has $249.31 million in cash and $196,000 in debt, giving a net cash position of $249.11 million or $9.70 per share.
| Cash & Cash Equivalents | 249.31M |
| Total Debt | 196,000 |
| Net Cash | 249.11M |
| Net Cash Per Share | $9.70 |
| Equity (Book Value) | 279.86M |
| Book Value Per Share | 10.90 |
| Working Capital | 250.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$84.02 million and capital expenditures -$18,000, giving a free cash flow of -$84.04 million.
| Operating Cash Flow | -84.02M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -84.04M |
| FCF Per Share | -$3.27 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |